Intermittent claudication: Pharmacoeconomic and quality-of-life aspects of treatment

PharmacoEconomics

Volumn 20, Issue 3, 2002, Pages 169-181

  Brevetti, Gregorio ^a   Annecchini, Roberta ^a   Bucur, Roxanna ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BERAPROST; CILOSTAZOL; CLOPIDOGREL; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MILRINONE; NAFTIDROFURYL; NICOTINIC ACID; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PROBUCOL; PROPIONYLCARNITINE; PROSTACYCLIN; SEROTONIN 2 ANTAGONIST; TICLOPIDINE;

ATHEROSCLEROSIS; BYPASS SURGERY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIET RESTRICTION; DISEASE COURSE; DISTRESS SYNDROME; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; EXERCISE; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HEALTH STATUS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERMITTENT CLAUDICATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; REVIEW; RISK FACTOR; STENT; STROKE; WALKING;

AGED; COST OF ILLNESS; HEALTH STATUS INDICATORS; HUMANS; INTERMITTENT CLAUDICATION; QUALITY OF LIFE; RISK FACTORS; WALKING;

EID: 0036241070     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200220030-00003     Document Type: Review

References (109)

1. Epidemiology of atherosclerotic disease in the lower limbs
2. Basic data related to the natural history of intermittent claudication
3. Peripheral arterial occlusive disease of the extremities in the United States: Hospitalization and mortality
4. Detailed diagnoses and procedures: National Hospital Discharge Survey, 1990
5. Peripheral arterial obliterative disease: Cost of illness in France
6. Mortality over a period of 10 years in patients with peripheral arterial disease
7. Subjective health of patients with peripheral vascular disease
8. Well-being and concerns of patients with peripheral arterial occlusive disease
9. Quality of life in patients with intermittent claudication: Relationship with laboratory exercise performance
10. Impact of intermittent claudication on quality of life
11. Intermittent claudication and risk of cardiovascular events
12. Epidemiology of intermittent claudication in middle-aged men
13. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories
14. Hyperhomocysteinemia: An independent risk factor for vascular disease
15. The influence of smoking cessation and hypertriglyceridemia on the progression of peripheral arterial disease and the onset of critical ischemia
16. Treatment of hyperlipidemia retards progression of the symptomatic femoral atherosclerosis: A randomized controlled trial
17. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: A report for the Regression Growth Evaluation Statin Study
18. Task force 6. Cost-effectiveness of assessment and management of risk factors
19. Cost-effectiveness of a smoking cessation program after myocardial infarction
20. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease
21. Cost-effective strategies for the management of vascular disease
22. The measured effect of stopping smoking on intermittent claudication
23. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: A meta-analysis
24. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S)
25. The cost-effectiveness of dietary and pharmacological therapy for cholesterol reduction in adults
26. An evidence-based assessment of NCEP Adult Treatment Panel II guidelines
27. Arteriosclerosis obliterans and associated risk factors in insulin-dependent and non-insulin-dependent diabetes
28. Smoking, lipids, glucose intolerance and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study
29. Lifetime benefits and costs of intensive therapy as practised in the diabetes control and complications trial
30. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus
31. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
32. Secondary prevention of vascular disease by prolonged antiplatelet treatment
33. Low-dose aspirin and subsequent peripheral arterial surgery in physicians' health disease study
34. United Kingdom transient ischaemic attack aspirin trial interim results
35. Prevention of myocardial infarction and stroke in patients with intermittent claudication: Effect of ticlopidine: Result from STIMS, the Swedish Ticlopidine Multicenter Study
36. Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: Results from the Swedish Ticlopidine Multicenter Study (STIMS)
37. An analysis of the side effects of ticlopidine
38. Thrombotic thrombocytopenic purpura associated with ticlopidine: A review of 60 cases
39. A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE)
40. Cardiovascular and renal advisory panel of the FDA
41. Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease
42. Realistic expectations for patients with intermittent claudication
43. Guidelines for peripheral percutaneous transluminal angioplasty for the abdominal aorta and lower extremity vessels
44. Exercise training improves functional status in patients with peripheral arterial disease
45. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis
46. Longterm neuroendocrine and metabolic effect of physical training in intermittent claudication
47. Hospital vs home-based exercise rehabilitation for patients with peripheral arterial occlusive disease
48. An epidemiological study of the value and limits of physical therapy/exercise therapy in Fontaine stage II arterial occlusive disease
49. Is percutaneous transluminal angioplasty better than exercise for claudication?. Preliminary results from a prospective randomised trial
50. Exercise training versus angioplasty for stable claudication: Long and medium term results of a prospective randomised trial
51. Randomised controlled trial of percutaneous transluminal angioplasty for intermittent claudication
52. Intermittent claudication: Surgical reconstruction or physical training?. A prospective randomised trial of treatment efficiency
53. Intermittent claudication in older patients: Practical treatment guidelines
54. Pentoxifylline efficacy in treatment of intermittent claudication: Multicenter, controlled, double-blind trial with objective assessment of chronic occlusive arterial disease patients
55. Trental 400 in the treatment of intermittent claudication: Results of long-term, placebo-controlled administration
56. Double-blind, crossover study of the clinical efficacy and the hemorheological effect of pentoxifylline in patients with occlusive arterial disease of the lower limbs
57. Drug treatment of intermittent claudication: A critical analysis of the methods and findings of published clinical trials, 1965-1985
58. Conservative management of intermittent claudication
59. A comparison of cilostazol and pentoxifylline for treating intermittent claudication
60. The effect of pentoxifylline on patients with intermittent claudication
61. Effects and limitations of pentoxifylline therapy in various stages of peripheral vascular disease of the lower extremity
62. Cilostazol
63. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial
64. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial
65. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication
66. Effect of milrinone on mortality in severe chronic heart failure
67. Comparison of the effect of cilostazol and milrinone on intracellular cAMP level and cellular function in platelets and cardiac cells
68. Propionyl-L-carnitine
69. Free radical scavenging is involved in the protective effect of L-propionyl-carnitine against ischemia-reperfusion injury of the heart
70. L-propionyl-carnitine as superoxide scavenger, antioxidant and DNA cleavage protector
71. Propionyl-L-carnitine in intermittent claudication: Double-blind, placebo-controlled, dose titration, multicenter study
72. Effect of propionyl-L-carnitine on quality of life in intermittent claudication
73. European multicenter study on propionyl-L-carnitine in intermittent claudication
74. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication
75. Carnitine-related alterations in patients with intermittent claudication: Indication for a focused carnitine therapy
76. Oral beraprost sodium, a prostaglandin I2 analogue, for intermittent claudication
77. Naftidrofuryl in intermittent claudication: A retrospective analysis
78. Peripheral vascular disorders: A pharmacoeconomic and quality of life review
79. Medical care and outcomes after pentoxifylline treatment for peripheral arterial disease
80. Procedure costs and outcomes associated with pharmacologic management of peripheral arterial disease in the Departments of Defense
81. Treatment costs of peripheral arterial occlusive disease in Germany: A comparison of costs and efficacy
82. The cost of underutilisation: Percutaneous transluminal angioplasty for peripheralvascular disease
83. The use of angioplasty, bypass surgery, and amputation in the management of peripheral vascular disease
84. Transcatheter therapies in peripheral and non coronary vascular disease: Introduction
85. Intermittent claudication: Be conservative
86. Revascularization for femoropopliteal disease: A decision and cost-effectiveness analysis
87. Cost-effectiveness of percutaneous treatment of iliac artery occlusive disease in the United States
88. Measuring quality of life in clinical trials: A taxonomy and review
89. Self-administration of a questionnaire on chest pain and intermittent claudication
90. Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease
91. Benefit of exercise conditioning for patients with peripheral arterial disease
92. Functional benefits of peripheral vascular bypass surgery for patients with intermittent claudication
93. Physical activity assessment methodology in the five-city project
94. Functional health and well-being in patients with severe atherosclerotic peripheral vascular occlusive disease
95. Correlating clinical indicators of lower-limb ischemia with quality of life
96. The impact of intermittent claudication on quality of life evaluated by the sickness impact profile technique
97. Clinical trials for claudication: Assessment of exercise performance, functional status, and clinical endpoints
98. Management of peripheral arterial disease
99. Cost-effectiveness of conservative and interventional treatment strategies in patients with intermittent claudication
100. Quality of life assessment in vascular disease: Towards a consensus
101. The claudication scale (CLAU-S): A new disease-specific quality of life instrument in intermittent claudication
102. Naftidrofuryl in quality of life (NIQOL): A Belgian study
103. Mesure de la qualitè de vie dans la claudication intermittente: Validation clinique d'un questionnaire
104. Quality of life of patients with peripheral arterial obliterative disease tested with ifenprodil tartrate: Results of an ARTEMIS study
105. Un nuovo questionario per la valutazione della qualità, della vita nel paziente affetto da claudicatio intermittens
106. Uncertainty in decision models analysing cost-effectiveness: The joint distribution of incremental cost and effectiveness evaluated with a non-parametric bootstraps method
107. Assessment of treatment in cancer
108. Integrating economic evaluations and quality of life assessments